Long-Term Care

CMS nixes reimbursement for several wound care products

Contemporary Long-Term Care Weekly, March 22, 2007

Following a late 2006 U.S. Food and Drug Administration ruling, CMS will no longer pay for several wound care products, including Xenaderm Ointment, reported Medicare & Reimbursement Advisor Weekly. Skilled nursing facilities (SNF) use Xenaderm as a topical treatment to promote the healing of decubitus/pressure ulcers. SNFs claimed the product, despite its high cost, saved time in the healing process and had positive clinical outcomes, which saved money over time. Additional wound care products no longer receiving Medicare reimbursement include BCT-Allenderm-T, trypsin complex, Optase Gel, Granulex, and Granulderm & TBC, reported Medicare & Reimbursement Advisor Weekly.

Most Popular

Related Articles